Olfactory dysfunction in general and impaired odor identification in particular, have been reported in Alzheimer's disease (AD). Olfactory testing may be a useful diagnostic aid for AD, but the types of odor most commonly affected need to be identified. This study aimed to determine pattern and types of odor affected in AD with the goal of improving clinical applicability. 54 outpatients with mild to moderate AD and 40 age and sex matched nondemented controls (NDC) were tested using British version of University of Pennsylvania Smell Identification Test (UPSIT; Sensonics, Inc, Haddon Heights, NJ) and data analysed to identify an optimal subset of UPSIT to best differentiate AD patients from controls. AD subjects had significantly lower UPSIT total scores than NDC. Random Forest with backward elimination identified 12 UPSIT items which accurately differentiated AD patients compared to controls (sensitivity, 0.89 and specificity, 0.83, positive predictive value of 0.889 and negative predictive value of 0.833). With MMSE, the accuracy improved to 96.7% with sensitivity of 100% and specificity 91.7%. The 12 smell items found to be most affected in AD subjects, falls into the categories of Chemicals, Fruits and Nuts, that reflects important attributes such as danger and food, known to be affected in people with AD and that has the potential to impair activities of daily living. The 12 items of British UPSIT most affected in AD subjects, provides a potential brief scale for early detection of AD in clinical settings.
INTRODUCTION
Olfactory dysfunction in general and impaired odor identification in particular have been reported in AD and are found to occur at early stages of the disease [1] . It has been indicated that involvement of the olfactory bulb and tract is one of the earliest events in the degenerative process on the central nervous system in AD [2] and also that tau pathology in the olfactory bulb increases with severity of AD [3] . All published reports of smell identification in AD have demonstrated deficits relative to healthy elderly [4] . Olfactory dysfunction has been suggested to be included in the diagnostic criteria of AD [5] . A recent meta-analysis (4) suggest that smell identification and then smell detection, is more strongly affected in AD than in Parkinson's disease (PD) -suggesting that AD patients are more strongly impaired on higher-order olfactory tasks involving specific cognitive processes.
The University of Pennsylvania Smell Identification Test (UPSIT) is widely used in AD research to assess smell identification deficits. Its applicability in many clinical practices, particularly in those in which geriatric or demented populations are tested, is limited by administration time. The AD subjects needed approximately 35 minutes to complete the test, whereas the controls needed about 20 minutes, when an examiner assisted all subjects with the test and allowed them unlimited time [6] . In a previous study we have found that AD patients required 27 minutes and NDC 18 minutes [7] .
Tests of olfaction are commonly based on total olfactory performance after exposure to multiple odors. Although it is well established that patients with AD perform significantly more poorly than matched controls, there is little information on whether their ability to identify specific odors is more impaired than the control subjects. We used British version of UPSIT to identify the selective pattern of olfactory deficits and compile an optimal subset of UPSIT items discriminating AD patients from control subjects, with the goal of improving clinical applicability. Association (NINCDS-ADRDA) criteria [8] . The exclusion criteria were: dementia other than AD; history of psychiatric disorder, including substance abuse; medical conditions that may alter cerebral functioning or other conditions known to affect olfactory functioning (e.g., common cold, blocked nasal passages, polyps etc.). Subjects had either no history at all of cigarette smoking or had stopped smoking for 20 years or more. Informed consent or assent, as appropriate, was taken from all the patients. The study had ethics approval from both the Joint Institute of Psychiatry and the South London and Maudsley ethics committee and the local ethics committee for Leicestershire Partnership NHS Trust.
SUBJECTS AND METHODS

Subjects
Non demented control subjects (NDC):
Eligible and interested non-demented control subjects (n=40) were recruited from the ongoing AD biomarker studies at the centre for this olfaction study. As part of these biomarker studies, subjects with AD and non-demented controls were recruited and assessed as per standard protocol described previously [9, 10] . Inclusion criteria: MMSE score range between 24 and 30 (inclusive), medication stable and good general health. Exclusion criteria:
Meeting DSM-IV criteria for dementia, significant neurological or psychiatric illness, significant unstable systematic illness or organ failure.
Assessments
Assessment included cognitive testing with MMSE [11] ; non-cognitive symptoms were assessed using Neuropsychiatric Inventory (NPI) [12] , daily activities with Bristol Activities of Daily Living Scale (BADL) [13] and smell identification function using University of Pennsylvania smell identification test (UPSIT) [14, 15] . UPSIT is a standardised test of smell identification with good test-retest reliability (r=0.95) and strong correlation with detailed olfactory threshold tests (r=0.80) [15] .
Statistics
Comparisons were made on demographic information, clinical characteristics, and cognitive and behavioural test results using the Chi-square Test for categorical outcomes and using 'rfe' in the R package 'CARET') was used to select a subset of UPSIT items which can accurately classify AD patients compared to controls. AD cases and controls were divided into a training (2/3) and an independent test dataset (1/3) such that the training set comprised equal ratios of each diagnostic group. We additionally tried to maintain equal female/male ratios as well as similar age, education and MMSE means for each diagnostic group between the two datasets.
Random Forest with RFE (i.e. backwards elimination) was used on the Training dataset using 100 Bootstraps on the top 40 UPSIT items in order to rank the UPSIT items according to their predictive power. 100 Bootstraps were used such that the training dataset was randomly split into a bootstrap training set (75%) which was used to build the Random Forest model and a bootstrap test set (25%) which was used to test the model. The bootstrapping was repeated keeping the top 35 to 10 analytes in steps of 5 and down to two analytes in steps of one. In each model the default setting for ntree=500 were used. For each subset of predictors the mean bootstrap testing performance was calculated using the "AUC" and based on this the optimal number of variables was identified. This was then used to build a final model in the complete training data, which was then tested with the independent test set. Finally, we used the "sizeTolerance" function in 'CARET', which takes into account the whole profile during 'rfe' and tries to pick a subset size that is small without sacrificing too much performance. This model was compared to models including a) Final model plus covariates (age, sex, and education) b) Final model plus MMSE.
RESULTS
None of the participants reported subjective impairment in olfaction. The sociodemographic and clinical comparisons between the AD subjects and the NDC are as described in Table 1 . The AD group scored higher on the baseline MMSE and UPSIT measures than NDC, and took longer to complete the UPSIT. There were no gender differences in the UPSIT scores in both groups (X2(1) =0.92, P=0.34). The NDC group had higher education years (p=0.001) than the AD group.
Multivariate analysis
Random Forest with recursive feature elimination was fitted on the 40 UPSIT items down to 2 UPSIT items of the training dataset and showed that the highest mean training (Table 2) .
Results for the Random Forest models, including a model with covariates only, a model which includes MMSE and a model including the 40 UPSIT items are displayed in Table 2 and ROC curves in Figure 1 . Table 1 . When looking at the Variable Importance measures during "rfe" after 100 Bootstraps it is seen that the greatest contribution to the model was made by motor oil, banana and coconut which produced a ROC curve of >80% for the rfe training set.
DISCUSSION
A subset of 12 of the 40 UPSIT items (British version) differentiated AD subjects from NDC accurately (86.7%) with a sensitivity of 88.9% and specificity of 83.3% on its own. With MMSE, the accuracy improved to 96.7% with sensitivity of 100% and specificity 91.7%. The accuracy with 12 items were as good as for 40 items, indicating that these 12 items are sufficient to differentiate the groups and there is no added advantage of doing the complete 40 items as the effect seem to level off.
The AD participants were deliberately chosen to be in the early stages (mild-moderate) of the disease, so that there is little question of their ability to understand and perform the smell test. None of the AD participants had speech or language difficulties. All participants were White Europeans except for 4 patients and 1 NDC.
The total UPSIT scores for AD and NDC subjects were similar to those reported in previous studies [16] [17] [18] [19] [20] . We did not find any significant effects of gender on olfactory identification deficits which is in keeping with previous studies [21] . A possible explanation could be that, as has been shown previously, gender differences decrease with increasing age [22] . The mean age of both our groups were 72 years (with the range between 45 and 90), which could be a possible reason why women in our normal elderly control group did not show an expected superiority on the odour identification task. Secondly, it is possible that the effects of pathological processes on olfactory functions are so large that they blur gender effects existing in the AD patients [21] .
There have been several studies that have looked at the specific UPSIT items (US version) which differentiated AD patients from controls. Of the 40 UPSIT items, the 5 items that maximally differentiated (p < 0.005) the Alzheimer's and control groups were bubble gum [6] . In another study, UPSIT data from control subjects, patients with mild cognitive impairment and AD patients were analysed to derive an optimal subset of items related to risk for Alzheimer's disease (i.e., healthy through mild cognitive impairment to early and moderate disease stages) [23] . The derived 10-item scale performed comparably with the UPSIT in classifying subjects, and it strongly predicted conversion to Alzheimer's disease on 2-year follow-up evaluation in patients with mild cognitive impairment. The items were Menthol, Clove, Leather, Strawberry, Lilac, Pineapple, Smoke, Soap, Natural gas and Lemon. According to a recent classification of odours, into 10 categories using non-negative matrix factorization (NMF) to odor profiling data for human odor percepts, the 12 items most affected in our AD patients fall into the categories of Chemicals, Fruits (citrus and noncitrus) and Popcorn (Nuts) [24] . Interestingly these categories reflect important attributes such as danger and food. Deficits in identification of odors in these categories could explain certain symptoms of AD, such as decreased sense of danger such as cooking related incidents, leaving gas cooker on due to inability to detect leaking gas, storage or ingestion of spoiled food and loss of weight.
There have also been reports looking into one specific odor identification deficit in AD patients. In one study participants with probable AD (N=18), mild cognitive impairment (MCI, N=24), other causes of dementia (OD, N=26) and matched controls (OC, N=26) were tested, with closed eyes, for their ability to detect an odor, one nostril at a time, using peanut butter [25] . A left nostril impairment of odor detection was present in all the patients with probable AD compared to controls (100% sensitive and 92% specific).
However, a recent study sought to replicate and expand this work by conducting 2 studies; one using the same methodology as Stamps et al and another using UPSIT 20 items on each nostril, and found that no meaningful asymmetry in smell perception was apparent [26] .
The limitations of the study are: firstly, although differences between the odors identified here and those identified in previous reports, can be accounted for to some degree by methodological differences (e.g., sample size, US vs British versions, statistical approaches), the lack of consistency in the odors identified as optimal across studies emphasizes the need for independent replication. Another explanation for variability across studies regarding specificity of odorants is that such odorants are not unitary entities and made up of number of chemicals [27, 28] . Even a single chemical can stimulate a range of receptors that overlap the receptive fields of other single compound stimuli [29] . Importantly, the number of receptors involved with different stimuli is unknown, even at the receptor sites between components of a single odor and much less the interactions that occur within the olfactory bulb [29, 30] . Hence, there can be considerable variability in stimuli across studies. The greater risk of impairment, associated with certain UPSIT items may be explained by ADrelated pathology in olfactory related brain areas which may differentially impact the neural circuitry, mediating odor processing [23] and this needs further investigation.
We did not test and compare UPSIT performance with other causes of dementia such as Lewy body dementia. However this is beyond the remit of our study and further work is needed to look at this.
For olfactory tests to be clinically useful for early detection of AD, they must be brief, sensitive to early pathological and functional changes and significantly add to the predictive accuracy of known demographic and clinical risk factors [23] . The proposed 12-item scale meets these criteria and can be self-administered by patients or carers with minimal supervision. Scoring is objective and needs minimal training, which can be reviewed and interpreted in the context of a clinical workup. Pending independent replication, this 12-item subset's potential diagnostic and predictive utility, make a strong case for including it as part of a standard clinical workup for patients with suspected AD. Specificity against other disorders such as PD also needs to be established, with neuropathological confirmation if possible. Finally, future cross-cultural validation studies will be needed to ascertain the discriminative and predictive potential of these derived items in a multi-ethnic British population.
In conclusion, if the proposed UPSIT subset's predictive accuracy for AD diagnosis is replicated and is comparable or superior to other early markers, it may, in combination with other diagnostic tests, help to improve early detection of AD in clinical settings. Author responsibilities: LV designed the study, carried out the data collection, performed statistical analysis and interpretation. AG, SB, MP and CM contributed to the data collection.
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